On the stock market since 2009, it operates in the world of health and science. It has 1,362 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 42% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $342.2M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 41% a year on average.
There is $429.5M in the vault; even if every debt were paid off, $342.2M would remain.
Over the last 12 months, company executives reported 34 buys and 12 sells. Management buying with its own money is usually read as a good sign.
The company’s market value is 81 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, AMEH sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AMEH is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.